Lisanti Capital Growth LLC Decreases Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Lisanti Capital Growth LLC trimmed its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 43.1% during the third quarter, Holdings Channel reports. The fund owned 43,011 shares of the company’s stock after selling 32,514 shares during the period. Lisanti Capital Growth LLC’s holdings in Tarsus Pharmaceuticals were worth $2,556,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Jennison Associates LLC increased its stake in shares of Tarsus Pharmaceuticals by 5.5% during the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after purchasing an additional 136,582 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Tarsus Pharmaceuticals by 25.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock worth $74,166,000 after buying an additional 250,367 shares during the last quarter. Geode Capital Management LLC increased its position in Tarsus Pharmaceuticals by 8.0% in the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock worth $37,859,000 after buying an additional 68,986 shares during the last quarter. Invesco Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 12.3% in the second quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock valued at $37,614,000 after buying an additional 101,978 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its position in shares of Tarsus Pharmaceuticals by 6.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 543,000 shares of the company’s stock valued at $21,997,000 after buying an additional 33,000 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $64.54 on Friday. The firm has a 50 day moving average of $77.54 and a 200-day moving average of $65.26. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The firm has a market capitalization of $2.74 billion, a P/E ratio of -31.95, a price-to-earnings-growth ratio of 0.95 and a beta of 0.59.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The business had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TARS has been the subject of several recent research reports. Barclays initiated coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective for the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $51.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th. Mizuho initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target on the stock. HC Wainwright upped their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research note on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $79.86.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at $70,792,837.41. This represents a 0.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.